CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
You may also be interested in...
Oral drugs are ruled exempt until 2014 from a new dialysis payment plan, and hopes are high for an osteoporosis drug to become a cancer blockbuster.
Inclusion of oral-only drugs in bundled payment will be delayed until 2014, allowing CMS to address pricing and data issues, but the decision does not alter the agency's interpretation that oral-only drugs should be a part of the bundle.
The opening of a national coverage analysis comes with a public request for CMS to establish Medicare coverage limitations for ESA use in pre-dialysis and dialysis renal disease patient populations.